The Indian Practitioner

Mayuresh Dilip Kiran ¹, Pooja Gharat ¹, Monali Vakharia ¹, Natarajan Ranganathan ²

Affiliations
1 Medical Services and Pharmacovigilance, Centaur Pharmaceuticals Pvt. Ltd.,
2 Kibow Biotech Inc., PA, USA

Abstract

Chronic kidney disease (CKD) is a global health issue with a high economic cost to health systems and one of the risk factor for cardiovascular disease (CVD). All stages of CKD are associated with decreased quality of life. CKD is usually asymptomatic until later stages. Probiotics are living micro-organism very well known for a role they in the prevention and reduction of risk factors for several diseases and are also capable of enhancing certain vital physiological functions. A normal human digestive tract contains about 400 types (strains) of probiotic bacteria that control and reduce the growth of harmful bacteria and promote a healthy digestive system. The application of probiotics to kidney health is an emerging area of medicine that has only recently come into attention of scientists. In CKD patients there is a build-up of poisonous wastes in the bloodstream due to the overloaded and impaired kidneys. Certain probiotic microorganisms can utilize urea, uric acid, creatinine and other toxins as nutrients for growth which helps eliminate them as fecal matter. Probiotic organisms transform the colon into a blood cleansing organ in cases where kidney fails to remove toxins from blood. Thus probiotics are new hope for CKD patients and can be used to delay progression of disease. We aim to compile the data of various researches and clinical trials being conducted to evaluate benefits of probiotics in CKD patients. Acknowledgements and Disclosures: This article is written with the medical writing support from Centaur Pharmaceuticals Pvt Ltd, the marketers of Renadyl™ in India (sourced from Kibow Biotech, USA).

Keywords

Chronic Kidney Disease (CKD), Probiotics and Uremic Toxins.

Full Text